drugset

drugset / Trial / NCT00400803

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

NCT00400803 ↗

Phase 2 Completed 38 enrolled Masonic Cancer Center, University of Minnesota Eli Lilly and Company · collab Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.

Timeline

Start: 2007-03
Primary completion: 2010-05
Completion: 2010-05

Publications

Dudek AZ, Kumar P, H Thaw SS, Cao Q, Pawloski P, Larson T. Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. Am J Clin Oncol. 2014 Apr;37(2):140-3. doi: 10.1097/COC.0b013e31826b9e12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Gemcitabine	Small molecule	2000 mg/m2	Intravenous

Indications